Ocugen, Inc. revenue
Ocugen, Inc.'s revenue was $4.4m in fiscal 2025, up 8.8% on the year before. Since fiscal 2020 ($43,000) it has grown at a compound 152.5% a year. Over the last twelve months it was $4.6m.
Revenue history
| Fiscal year | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 43 | 0 | 2,488 | 6,036 | 4,055 | 4,413 | 4,580 |
| Growth on the year before | — | — | — | — | — | — | — | −100.0% | — | +142.6% | −32.8% | +8.8% | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Ocugen, Inc. | $4.6m | -3.7% | 26.3% |
| Ensysce Biosciences, Inc. | $4.5m | -39.3% | 14.6% |
| Entrada Therapeutics, Inc. | $4.7m | -94.1% | — |
| Bolt Biotherapeutics, Inc. | $4.7m | 12.8% | -11.5% |
| Curis Inc | $4.3m | -62.2% | -25.0% |
| Rani Therapeutics Holdings, Inc. | $4.9m | 306.4% | — |
Compare with peers
- Ensysce Biosciences, Inc. revenue
- Entrada Therapeutics, Inc. revenue
- Bolt Biotherapeutics, Inc. revenue
- Curis Inc revenue
- Rani Therapeutics Holdings, Inc. revenue
Head to head: ENSC vs OCGNOCGN vs TRDABOLT vs OCGNCRIS vs OCGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies